WO2010149215A1 - Compositions pharmaceutiques d'artésunate solubles dans des solutions aqueuses - Google Patents

Compositions pharmaceutiques d'artésunate solubles dans des solutions aqueuses Download PDF

Info

Publication number
WO2010149215A1
WO2010149215A1 PCT/EP2009/057968 EP2009057968W WO2010149215A1 WO 2010149215 A1 WO2010149215 A1 WO 2010149215A1 EP 2009057968 W EP2009057968 W EP 2009057968W WO 2010149215 A1 WO2010149215 A1 WO 2010149215A1
Authority
WO
WIPO (PCT)
Prior art keywords
artesunate
hydroxycarbohydrate
carrier
pharmaceutical composition
pharmaceutical compositions
Prior art date
Application number
PCT/EP2009/057968
Other languages
English (en)
Inventor
Frans Herwig Jansen
Original Assignee
Dafra Pharma N.V.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dafra Pharma N.V. filed Critical Dafra Pharma N.V.
Priority to PCT/EP2009/057968 priority Critical patent/WO2010149215A1/fr
Publication of WO2010149215A1 publication Critical patent/WO2010149215A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Definitions

  • the present invention relates to pharmaceutical compositions in powder form comprising an anti-malarial agent. Further, the present invention relates to a unit dose comprising the pharmaceutical compositions. Furthermore, the present invention relates to a unit dose comprising the pharmaceutical compositions for use in the treatment of malaria .
  • malaria is a mosquito-borne disease or vector-borne infection, and is considered as one of the most important diseases and death factors in tropical countries.
  • the number of malaria infected patients has increased in recent years probably due to resistance of the parasite to chloroquine, an affordable and widely available anti-malarial drug, as well as the resistance to sulfadoxine-pyrimethanine, a more recent anti-malarial medicament.
  • Other drugs are consequently necessary to treat malaria.
  • Novel efficient anti-malarial drugs based on artemisinin derivatives were discovered, developed and were proved to be highly efficient anti-malarial medicines, such as artemisinin and derivatives thereof.
  • Artesunate is a derivative of artemisinin and is known for the treatment of malaria infected patients. The efficiency of the drug generally provides clearance of the fever within 16 to 25 hours. Artesunate is soluble in aqueous solutions and can be administrated orally, rectally or via intramuscular or intravenous injection. A common form of artesunate is a bicarbonate artesunate, which has to be prepared immediately before use, with artesunic acid in presence of bicarbonate. However, according to Ipca Laboratories Ltd in their document Crusade against Malaria, this composition needs to be vigorously mixed for several minutes in order to dissolve the ingredients and avoid cloudy solutions.
  • Cloudy solutions, or opaque suspensions inherently imply a decrease in dosing accuracy, especially when such dosing is prepared by not sufficiently trained medical personnel, such as in most regions where malaria is an issue. Further, cloudy solutions, or suspensions, reduce the efficiency of the drug absorption into the body. Thus, cloudy solutions, or medicinal preparations comprising undissolved ingredients, are generally undesirable.
  • compositions in powder form, comprising artesunate, a pharmaceutically acceptable hydroxycarbohydrate carrier and a phosphate salt, wherein in aqueous form, the composition has a pH in the range of 6.9 to 9.2 and wherein the ratio between the artesunate and the pharmaceutically acceptable hydroxycarbohydrate carrier is in the range of 0.5:1.5 to 1.5:0.5 by weight.
  • a substantially soluble artesunate preparation as described herein, is defined as an aqueous preparation suitable for parenteral, such as intramuscular, administration with no visibly observable undissolved ingredients.
  • parenteral such as intramuscular
  • administration with no visibly observable undissolved ingredients.
  • the present inventors also surprisingly observed that the present composition is stable, i.e., no visible precipitation is observed, over a prolonged period such as over hours to days. This stability also contributes to the beneficial properties of the present pharmaceutical composition.
  • compositions according to the invention are surprisingly suitable to obviate the above mentioned dosage problem of the artesunate by providing pharmaceutical compositions substantially soluble in aqueous solutions .
  • the powder form of the pharmaceutical compositions is inherently stable over months for shipping, storage and handling purposes.
  • the pH of the pharmaceutical compositions in aqueous solution is in the range of 6.9 to 9.2, such as 6.9, 7.0, 7.1, 7.2, 7.4, 7.6, 7.8, 8.0, 8.2, 8.4, 8.6, 8.8, 9.0, and 9.2.
  • the pharmaceutical compositions according to the invention in aqueous form, have a pH in the range of 6.9 to 8.0, preferably 6.9 to 7.5, more preferably 7.2.
  • the ratio between the artesunate and the pharmaceutically acceptable hydroxycarbohydrate carrier is in the range of 0.5:1.5 to 1.5:0.5 by weight, such as 0.5:1.5, 0.6:1.4, 0.7:1.3, 0.8:1.2, 0.9:1.1, 1:1, 1.1:0.9, 1.2:0.8, 1.3:0.7, 1.4:0.6 and 1.5:0.5.
  • compositions according to the present invention comprise a pharmaceutically acceptable hydroxycarbohydrate carrier, wherein the hydroxycarbohydrate carrier is mannitol.
  • the pharmaceutical compositions according to the present invention comprise a pharmaceutically acceptable hydroxycarbohydrate carrier, wherein the hydroxycarbohydrate carrier is micronized mannitol. Micronized mannitol is a particular powder form of mannitol, wherein the grains of the powder have a diameter of 1 to 100 microns.
  • the pharmaceutical compositions according to the present invention comprise a pharmaceutically acceptable hydroxycarbohydrate carrier, wherein the hydroxycarbohydrate carrier is sorbitol.
  • the pharmaceutical compositions according to the present invention comprise a pharmaceutically acceptable hydroxycarbohydrate carrier, wherein the hydroxycarbohydrate carrier is xylitol.
  • the pharmaceutical compositions according to the present invention comprising artesunate are in an ultrathin powdered form.
  • Ultrathin artesunate is artesunate which has been treated in order to select the thinner grains of the powder.
  • the present invention relates to a unit dose comprising a sealable container comprising a pharmaceutical composition in powder form according to the present invention for the treatment of malaria.
  • a unit dose is packaging of a medicament suitable for one single dose.
  • Said sealable container is generally known for pharmaceutical use and can be a vial, a capsule or a flask for example.
  • a sealable container according to the present invention is a substantially air and moisture impermeable container after sealing.
  • the unit dose according to the present invention comprises artesunate with a weight in the range of 50 to 200 mg, preferably 75 to 150 mg, more preferably 100 mg.
  • the indicated amounts of artesunate are generally accepted efficient dosages of the anti-malarial agent.
  • the unit dose according to the present invention in aqueous form, has a volume in the range of 0.25 to 5 ml, preferably 1 to 3 ml, more preferably 2 ml.
  • the indicated volumes of solution are generally accepted volumes for parenteral, such as intramuscular, administration.
  • methods for the preparation of a pharmaceutical composition comprising: a) dissolving of a pharmaceutical composition in powder form comprising artesunate, a pharmaceutically acceptable hydroxycarbohydrate carrier and the buffer in powder form in an aqueous solution to obtain a clear solution; b) filtering and sterilizing the solution; c) freeze-drying of the solution.
  • freeze-drying process also called lyophilisation
  • lyophilisation is a dehydration method allowing better transport and handling of materials.
  • methods for the preparation of the pharmaceutical composition have a pH of 7.2 when dissolved in aqueous solutions .
  • the pharmaceutical compositions or the unit doses according to the present invention are suitable for the treatment of malaria.
  • the medical use according to the present invention comprises the treatment comprises by parenteral injection.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

La présente invention porte sur des compositions pharmaceutiques sous forme de poudre comprenant un agent antipaludique. De façon spécifique, la présente invention porte sur les compositions pharmaceutiques, sous forme de poudre, comprenant de l'artésunate, un véhicule glucide hydroxylé pharmaceutiquement acceptable et un tampon phosphate, la composition ayant, sous forme aqueuse, un pH dans la plage de 6,9 à 9,2 et le rapport entre l'artésunate et le véhicule glucide hydroxylé pharmaceutiquement acceptable étant dans la plage de 0,5:1,5 à 1,5:0,5 en poids. En outre, la présente invention porte sur une dose unitaire comprenant les compositions pharmaceutiques. Encore en outre, la présente invention porte sur une dose unitaire comprenant les compositions pharmaceutiques destinée à être utilisée dans le traitement de la malaria. Le véhicule glucide hydroxylé préféré peut être le mannitol, le sorbitol ou le xylitol.
PCT/EP2009/057968 2009-06-25 2009-06-25 Compositions pharmaceutiques d'artésunate solubles dans des solutions aqueuses WO2010149215A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
PCT/EP2009/057968 WO2010149215A1 (fr) 2009-06-25 2009-06-25 Compositions pharmaceutiques d'artésunate solubles dans des solutions aqueuses

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/EP2009/057968 WO2010149215A1 (fr) 2009-06-25 2009-06-25 Compositions pharmaceutiques d'artésunate solubles dans des solutions aqueuses

Publications (1)

Publication Number Publication Date
WO2010149215A1 true WO2010149215A1 (fr) 2010-12-29

Family

ID=42115824

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2009/057968 WO2010149215A1 (fr) 2009-06-25 2009-06-25 Compositions pharmaceutiques d'artésunate solubles dans des solutions aqueuses

Country Status (1)

Country Link
WO (1) WO2010149215A1 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104414977A (zh) * 2013-09-09 2015-03-18 重庆汇智药物研究院有限公司 一种注射用青蒿琥酯和l-精氨酸组合物及其制备方法
WO2022023479A1 (fr) 2020-07-31 2022-02-03 KBHB Consult GmbH Molécules ciblant la protéine ribosomale rpl35/ul29 pour une utilisation dans le traitement de maladies, en particulier de l'épidermolyse bulleuse (eb)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030171424A1 (en) * 2002-03-07 2003-09-11 Lin Ai J. Intravenous formulation of artelinic acid for treatment of severe and complicated malaria
US20030203875A1 (en) * 2002-03-07 2003-10-30 Hartell Mark G. Artemisinins with improved stability and bioavailability for therapeutic drug development and application
US20040038933A1 (en) * 2000-10-20 2004-02-26 Yutaro Kaneko Pharmaceutical compositions, dose and method for treating malaria
WO2007146288A2 (fr) * 2006-06-13 2007-12-21 Walter Reed Army Institute Of Research (Wrair) Méthodes de formulation et de fabrication d'acide artésunique pour injection

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040038933A1 (en) * 2000-10-20 2004-02-26 Yutaro Kaneko Pharmaceutical compositions, dose and method for treating malaria
US20030171424A1 (en) * 2002-03-07 2003-09-11 Lin Ai J. Intravenous formulation of artelinic acid for treatment of severe and complicated malaria
US20030203875A1 (en) * 2002-03-07 2003-10-30 Hartell Mark G. Artemisinins with improved stability and bioavailability for therapeutic drug development and application
WO2007146288A2 (fr) * 2006-06-13 2007-12-21 Walter Reed Army Institute Of Research (Wrair) Méthodes de formulation et de fabrication d'acide artésunique pour injection

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104414977A (zh) * 2013-09-09 2015-03-18 重庆汇智药物研究院有限公司 一种注射用青蒿琥酯和l-精氨酸组合物及其制备方法
WO2022023479A1 (fr) 2020-07-31 2022-02-03 KBHB Consult GmbH Molécules ciblant la protéine ribosomale rpl35/ul29 pour une utilisation dans le traitement de maladies, en particulier de l'épidermolyse bulleuse (eb)
DE102020120218A1 (de) 2020-07-31 2022-02-03 KBHB Consult GmbH Gegen das ribosomale Protein rpL35/uL29 gerichtete Moleküle zur Verwendung in der Behandlung von Erkrankungen, insbesondere Epidermolysis bullosa (EB)

Similar Documents

Publication Publication Date Title
CN103622950B (zh) 抗疟疾药物组合物
EP3206665B1 (fr) Composition de mélatonine liquide anhydre
US10092523B2 (en) Long acting pharmaceutical compositions
KR102656841B1 (ko) 레파뮬린의 주사가능한 약제학적 제형
Li et al. Pharmacokinetic and pharmacodynamic profiles of rapid-acting artemisinins in the antimalarial therapy
WO2010149215A1 (fr) Compositions pharmaceutiques d'artésunate solubles dans des solutions aqueuses
AU2011273064A1 (en) Pharmaceutical compositions comprising paracetamol and process for preparing the same
WO2012001494A2 (fr) Compositions pharmaceutiques contenant du paracétamol et procédé pour les préparer
TWI684451B (zh) 水飛薊賓注射劑及其製備方法
RU2414898C1 (ru) Фармацевтическая композиция в форме раствора для инъекций, обладающая ноотропной активностью, и способ ее получения
US20140011830A1 (en) Artemisinin-Based Combination Therapy For Treating Parasitic Mediated Disease
EP2162154B1 (fr) Concentré d'esmolol coloré
WO2011009956A1 (fr) Solution aqueuse injectable contenant de l'artésunate
WO2015041722A1 (fr) Traitement combiné amélioré à base d'artémisinine permettant de traiter une maladie à médiation par des parasites
WO2022091122A1 (fr) Formulations de remdesivir stables
KR102323339B1 (ko) 정맥내 항바이러스 치료
US20140256761A1 (en) Enhanced artemisinin-based combination therapy for treating parasitic mediated disease
CN101491519B (zh) 一种银杏内酯注射剂及其制备方法
UA75620C2 (en) Stable pharmaceutical form of paclitaxel and method for the preparation thereof
RU2405554C1 (ru) Средство для лечения туберкулеза
US20220305023A1 (en) Chlorophyllin Containing Pharmaceutical Composition For Prevention Of Pathogenesis Of Coronavirus Disease
Shah et al. Formulation and evaluation of levocetirizine dihydrochloride mouth dissolving tablets
JP6033931B2 (ja) 有機溶媒無含有ゲムシタビン水溶液組成物
RU2487702C2 (ru) Лекарственное средство для лечения туберкулеза
CN114832087A (zh) 还原型谷胱甘肽在制备具有溶解夏科-莱登晶体作用的制剂中的应用

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09779948

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 09779948

Country of ref document: EP

Kind code of ref document: A1